蛋白琥珀酸铁口服溶液联合罗沙司他或rhEPO在非透析肾性贫血患者中的应用比较  

Comparison of the Application of Protein Succinylate Iron Oral Solution Combined with Rosuvastatin or rhEPO in Non-Dialysis Renal Anemia Patients

作　　者：宋大莉 袁玲 王晓娟[1] 齐金秋 SONG Dali;YUAN Ling;WANG Xiaojuan(The First Affiliated Hospital of Anhui University of Technology/Huainan First People's Hospital,Anhui Huainan 232007,China)

机构地区：[1]安徽理工大学第一附属医院/淮南市第一人民医院药学部,安徽淮南232007

出　　处：《河北医学》2023年第12期2087-2092,共6页Hebei Medicine

基　　金：国家自然科学基金项目(编号:81503080)。

摘　　要：目的:比较蛋白琥珀酸铁口服溶液联合罗沙司他或联合重组人红细胞生成素(rhEPO)在非透析肾性贫血患者中的应用效果。方法:选取我院2020年4月至2022年10月收治的120例住院以及门诊非透析肾性贫血患者为对象,采用简单随机法分为两组。对照组给予蛋白琥珀酸铁口服溶液联合rhEPO治疗,观察组给予蛋白琥珀酸铁口服溶液联合罗沙司他治疗。检测两组肾功能指标、贫血指标、铁代谢指标的差异,统计两组不良反应发生率。结果:两组治疗前后肾功能相关因子比较,差异没有统计学意义(P>0.05)。观察组肾功能指标治疗前后差值与对照组比较,差异没有统计学意义(P>0.05)。两组治疗前贫血相关指标比较,差异没有统计学意义(P>0.05)。与本组治疗前比较,两组血红蛋白(Hb)、红细胞比容(HCT)治疗后升高,观察组Hb、HCT治疗前后差值大于对照组(P<0.05),两组未成熟网织红细胞比率(IRF)治疗前后比较,差异没有统计学意义(P>0.05)。两组治疗前铁代谢指标比较,差异没有统计学意义(P>0.05)。与本组治疗前比较,两组铁蛋白、转铁蛋白饱和度治疗后升高,总铁结合力治疗后降低,观察组铁代谢指标治疗前后差值大于对照组(P<0.05)。观察组累计不良反应发生率为11.67%(7/60)与对照组的10.00%(6/60)比较,差异没有统计学意义(P>0.05)。结论:蛋白琥珀酸铁口服溶液联合罗沙司他治疗非透析肾性贫血对贫血指标、铁代谢指标的改善均优于蛋白琥珀酸铁口服溶液联合rhEPO,同时可保证安全性,值得临床推荐。Objective:To compare the application effects of protein succinylate iron oral solution combined with rosuvastatin or combined with recombinant human erythropoietin(rhEPO)in non-dialysis renal anemia patients.Methods:A total of 120 inpatient and outpatient non-dialysis renal anemia patients admitted to our hospital from April 2020 to October 2022 were selected and divided into two groups using a simple randomization method.The control group was treated with protein succinylate iron oral solution combined with rhEPO,while the observation group was treated with protein succinylate iron oral solution combined with rosuvastatin.Differences in renal function indicators,anemia indicators,and iron metabolism indicators between the two groups were examined,and the incidence of adverse reactions was recorded.Results:There was no significant difference in renal function related factors between the two groups before and after treatment(P>0.05).There was no significant difference in renal function index between observation group and control group before and after treatment(P>0.05).There was no significant difference in anemia-related indicators between the two groups before treatment(P>0.05).Compared with before treatment,hemoglobin(Hb)and erythrocyte specific volume(HCT)of the two groups were increased after treatment,and the difference of Hb and HCT before and after treatment of the observation group was greater than that of the control group(P<0.05),and the immature reticulum ratio(IRF)between the two groups before and after treatment had no significant difference(P>0.05).There was no significant difference in iron metabolism between the two groups before treatment(P>0.05).Compared with the control group before treatment,the saturation of ferritin and transferrin in the two groups increased after treatment,and the total iron binding capacity decreased after treatment.The difference of iron metabolism indexes in the observation group before and after treatment was greater than that in the control group(P<0.05).The cumulativ

关 键 词：非透析肾性贫血 蛋白琥珀酸铁口服溶液 罗沙司他 重组人红细胞生成素 

分 类 号：R692.5[医药卫生—泌尿科学]